GALECTIN THERAPEUTICS INC — Director's Dealing 2015

Feb 2, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2015-01-29

Reporting Person: TRABER PETER G (President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-01-29	Stock option (right to buy)	$3.45	A	134000	Acquired	2025-01-29	Common stock (134000)	Direct

Footnotes

F1: The options vest as follows: 25% immediately, and the remaining 75% in equal installments on a monthly basis over a period of three years.